Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study discusses the role of physicians and pharmaceutical companies as entrepreneurial actors in off-label drug use, arguing they may advance patient care more quickly than regulatory agencies.

This study discusses the prevalence and ethical considerations of off-label drug use in dermatology, emphasizing differing perspectives on informed consent between patients and physicians.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.

This review discusses the off-label use of drugs and emphasizes the need for standardized guidelines due to varying international regulations and safety concerns, but reports no new clinical results.

This study found that off-label drug use was prevalent in Saudi Arabia, particularly among adults and geriatrics for depression and diabetes mellitus, with antidepressants and antidiabetics most commonly prescribed.

This study found that after a health warning, off-label flutamide use by women reduced significantly in Spain, although misuse among ambulatory patients remains an issue.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

This study discusses the use of low-dose oral minoxidil for hair loss, noting that while it is popular and considered safe, it can mimic Cantú syndrome effects such as hypertrichosis and pericardial effusion, necessitating careful monitoring and caution during prescription.

This study found that spironolactone was not independently associated with increased breast cancer recurrence and may be considered for treating alopecia in survivors.

This review discusses the off-label use of drugs like Minoxidil, Aripripazole, and others, providing insights for physicians and pharmacists but reports no new clinical findings.

This article narrates a case where a patient with androgenetic alopecia faced high out-of-pocket costs for finasteride 1 mg and sought to reduce expenses by requesting a prescription for 5 mg tablets typically used for BPH, which are covered by insurance.

This retrospective study at the University Clinical Centre in Gdańsk reported that 77.9% of patients with alopecia areata were treated with off-label pharmacotherapy, predominantly glucocorticosteroids, highlighting a reliance on these therapies in European clinical practice.

This review discusses the integration of drug repurposing with personalized medicine through off-label prescribing and reports no new results, highlighting the potential for systematic exploration using omics technologies.

This article discusses challenges primary care physicians face in diagnosing and treating depression, noting that up to one-third of antidepressant prescriptions involve non-indicated use; it also introduces FDA-approved treatments, esketamine nasal spray, and brexanolone IV injection.

Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.

This study expands the Drug Ontology to include therapeutic indications for resistant hypertension, malaria, and opioid abuse research, providing a framework for additional drug use representations beyond their original design.

This study found that despite only topical minoxidil and oral finasteride being approved for androgenetic alopecia in Spain, dermatologists commonly prescribe various off-label treatments for both male and female patients.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

This case series reported incidents of iatrogenic Cushing's Syndrome linked to high doses of intralesional corticosteroid injections and mesotherapy regimens, highlighting the need for cautious prescription practices and further research on mesotherapy safety.

This study found that from 2011 to 2015, a substantial portion of women in the Netherlands dispensed finasteride or dutasteride were not using adequate contraception, prompting calls for improved risk management.

This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.

This review examines existing research and clinical trials on the use of dupilumab for various skin, respiratory, and gastrointestinal disorders, but it reports no new clinical findings.

This article reviews the history and impacts of direct-to-consumer advertising of prescription drugs in the U.S. and reports no new research findings; it discusses implications for health policy debates.

This systematic review assessed the off-label use of topical Ruxolitinib cream for various skin conditions and found it effective for lichenoid and granulomatous dermatoses, though results for alopecia areata were inconsistent. The authors indicate that further research is warranted to confirm these findings.

This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.

In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.

This article discusses the FDA approval of bremelanotide for premenopausal women with hypoactive sexual desire disorder and reports no clinical results.

In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.

This study identified significant patient frustration with limited access to treatments for alopecia areata in Germany, exacerbated by the absence of health insurance reimbursement for necessary medications.